Clinical Trials Directory

Trials / Completed

CompletedNCT02679469

A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Otsuka Pharmaceutical Co., Ltd. · Industry
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

The safety, tolerability, and pharmacokinetics of nalmefene at a single oral dose of 10 mg in healthy Japanese male subjects will be evaluated.

Conditions

Interventions

TypeNameDescription
DRUGnalmefene hydrochloride 10 mg

Timeline

Start date
2016-02-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2016-02-10
Last updated
2017-04-18
Results posted
2017-04-18

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT02679469. Inclusion in this directory is not an endorsement.